Acknowledgements

The following persons and organizations are thanked for their comments and other contributions to the evaluation and revision of the Guidelines; their help is gratefully acknowledged.

N.D. Achu, Commonwealth Pharmaceutical Association, Cameroon; M.G. Andersen, Rotary Australia; S. Anderson, Astra Pharmaceuticals Pty. Ltd., Australia; Sr. Angelina, Trinity Hospital, Malawi; B. Assam, South West Provincial Special Fund for Health, Cameroon; S. Barbereau, Pharmaciens Sans Frontières, Comité International, France; B. Barnes, Glaxo Wellcome plc., UK; P.G. Bindokas, Humanitarian Aid Commission, Lithuania; L. Blok, MSF, Holland; O. Brasseur, International Centre for Childhood and the Family, France; A. Brúzas, Order of Malta, Lithuania; F. Bürger & K. Zwingenberger, Grünenthal GmbH, Germany; K. Carter & J. Desautelle, AmeriCares, USA; J. Chamousset, Order of Malta, Benin; L.S. Charimari, Provincial Medical Directorate, Zimbabwe; N. Chebotarenco, Association “Drugs”, Republic of Moldova; P.M. Chenaparampil, Alleppey Diocesan Charitable and Social Welfare Society, India; A. Chidarikire, Ministry of Health and Child Welfare, Zimbabwe; J.C. Chin Loy, Sisters of the Poor, Philippines; Z. Chlap, Order of Malta, Poland; B.D. Colatrella, Merck & Co. Inc., USA; D. Collier, Janssen Pharmaceutica, Belgium; E.M. Connolly, Hoechst Marion Roussel Inc., USA; G. Coughlin, Order of Malta, El Salvador; A. Damdinsuren, Agency for Quality Assurance of Drugs, Mongolia; R.A. Davey, Memorial Christian Hospital, Bangladesh; C. Dedza, Mlambe Hospital, Malawi; C. Dick, Ekwendeni Hospital, Malawi; L. Dindonis, International Veterinary Educational Assistance, USA; K. Ditz, Merck KGaA, Germany; D. Djamilatou, PEV/SSP/ME, Conakry, Guinea; C. Drown, Medical Supplies Department, Nepal; T. Dubuque, Crudem Foundation, USA; R.B. Elens, Holy Family Hospital, Malawi; K. Ellerbroek, Bayer AG, Germany; A.J. Elphick, Novo Nordisk A/S, Denmark; A. Fadoul, Centers for Development and Health, Haiti; G. Fiorentino, Order of Malta, Panama; G. Folkedal, Norway; G.-B. Forte, WHO/EURO; M. Gastellu Etchegorry, MSF, France; Cpt. N. Gaza, MOD, Zimbabwe; G. Gedevanishvili, UMCOR, Georgia; R. Geursen & G. Küsters, Hoechst Marion Roussel, Germany; P.A. Gibson, Eli Lilly and Company, USA; J. Glenn, Smith Kline Beecham, USA; M. Greiff, Intercare, UK; F.C. Griz-Tesorero, Order of Malta, Chile; C. Gursky, Bayer Corporation, USA; S. Gvörgy, Malteska Dobrotvorna Organizacija, Jugoslavije; H. Haga, Nippon Glaxo Ltd.; M. Healy, Trócaire, Ireland; E. Hesse, MSF, Luxembourg; H. Hoppe, Bristol-Myers Squibb GmbH, Germany; Horizons Santé, Cameroon; B. Irvine, Pharmaceutical Society of New Zealand; B. Jøldal, Sandvika Apotek, Norway; P.A. Jotterand, Pharmaciens Sans Frontières, Comité International, France; K. Kafidi, Ministry of Health and Social Services, Namibia; T. Kaneko, Kirin Brewery Co. Ltd., Japan; J.P. Kelsall, MAP International, Canada; R.V. Kesteren-Archen, International Pharmaceutical Federation, Netherlands; H. Kienzl, Zeneca GmbH, Germany; G. Kimball, UMCOR, Haiti; W. Kollmann, Knoll AG, Germany; W. Kotkowski, Sihanouk Hospital Centre of HOPE, Cambodia; J. Krauskopf, Order of Malta, Croatia; C.E. Kuhinka, Wyeth-Ayerst Pharmaceuticals, USA; M. Kurian, Christian Medical Commission, Churches’ Action for Health, World Council of Churches, Switzerland; E. Larsson, DANIDA, Kenya; J.F. Ledesma, St. Luke’s Medical Centre, Philippines; P. Le Jacq, Maryknoll Missioners, United Republic of Tanzania; D. Lejoyeux, Tulipe, France; J.P. Lepers, Institut Léprologie Appliquée, Senegal; D. Lockyer, Overseas Pharmaceutical Aid for Life, Australia; J.-D. Lormand, MSF, Switzerland; A. Lungu, Swaziland; J. McDonald, St. Vincent de Paul Society, Australia; H. Maisano, World Vision, Australia; J. Mamedov, UMCOR, Azerbaijan; A. Masel & K.-J. Schlabe, Berlin-Chemie AG, Germany; F. Matthys, MSF, France; S. Meier, MAP International, USA; M. Minkaila, Direction Nationale de la Santé Publique, Mali; A. Møller, Leo Pharmaceutical Products Ltd. A/S, Denmark; Mongolemimpex, Mongolia; C. Mugadza, Datlabs Pvt. Ltd., Zimbabwe; C.Y. Mwasha, Muhimbili Health Centre, United Republic of Tanzania; Y. Nakano, Fujisawa Pharmaceutical Co., Ltd., Japan; G. Nanu, Cible, Cameroon; H. Norikyo & I. Kitamaru, Fuso Pharmaceutical Industries Ltd., Japan; M. O’Donohue, Catholic Medical Mission Board Inc., USA; G.B. Okelo, University of Tropical Medicine and Technology, Kenya; B. Olsen, International Federation of Red Cross and Red Crescent Societies, Switzerland; E.M.A. Ombaka, Pharmaceutical Programme, Community Initiatives Support Services International, Kenya; J. O’Neill, Save the Children Fund, Australia; Order of Malta, Dominican Republic; A.L. Oviedo, Ministerio de Salud y Previsión Social de Bolivia; D.M. Padgett, Interchurch Medical Assistance Inc., USA; R. Paltridge, Crusade Mercy Ministries, Australia; T. Parts, State Agency of Medicines, Estonia; B. Pastors, Action Medeor, Germany; C. Person, Johnson and Johnson, USA; A. Petersen, DIFÄM, Germany; Pharmaceutical Product Donation Steering Committee, USA; The Pharmacist, Health Services Department, Zimbabwe; G.H. de Pommery, Oeuvres Hospitalières Françaises de l’Ordre de Malte, France; W.L. Prelesnik, International Aid Inc., USA; S.K. Proctor, Mayaka Health Centre, Malawi; F.T. Puls, Memisa Medicus Mundi, Netherlands; N. Que, Christian Health Association of Malawi; M. Raijmakers, Wemos, Netherlands; Ramakrishna Mission Ashrama, India; Dr. Rakotomanana, Direction des Pharmacies, Madagascar; R.W. Rice, Asian Outreach Australia Inc., Australia; E.J. Ridder, Ministry of Development Cooperation, Netherlands; J. Rigal, MSF; C.C. Robert, Presbyterian Medical Institutions, Cameroon; M.C. Robert, Hôpital General de Kinshasa, Democratic Republic of the Congo; L. Rolver, Nycomed Amersham, USA; J. Roos, Centro de Obras Sociales, Peru; C.J. Rumball, CAN MAP, Canada; J. Russo, Partnership for Quality Medical Donations, USA; Sr. Sabina, Our Lady of Providence Hospital, India; Sadebay, Cameroon; H. Sandbladh, International Federation of Red Cross and Red Crescent Societies, Switzerland; M. Sarkar, Community Development Medicinal Unit, India; H. Sassounian, United Armenian Fund, USA; C. Saunders, UNFPA, USA; P. Saunders, Essential Drug Project, OXFAM, UK; R. Scharf, Institute of Haematology and Blood Transfusion, Poland; J. Schmick, World Vision, USA; Cpt. Sekouba-Bangoura, Order of Malta, Guinea; N.S. Snarskis, Order of Malta, Latvia; B. Snell, Macfarlane Burnet Centre for Medical Research, Australia; J.A. Soltz, Prosalud, Bolivia; S. Sopczynski, Medical Mission Sisters, Ethiopia; G. Stark, Kalene Mission Hospital, Zambia; U. Suna, Evangelical Mission Hospital, India; J. Svendsen, Interagency Procurement Services Office, United Nations Development Programme, Denmark; G. Szalay, WHO/SUP/DBP; D.W. Tarkieh, Needy Children Centre of Africa International, Ghana; L. Taylor, Kyrgyzstan; S. Teper, Ministry of Health and Social Welfare, Poland; D. Thierry, Centre de Santé de Lagdo, Cameroon; K. Timmermans, WHO Office, Indonesia; M. Torongu, Commonwealth Pharmaceutical Association, Zimbabwe; A. Toumi, Direction de la Pharmacie et du Médicament, Tunisia; United Nations Children’s Fund, Supply Division, Denmark; I.V. Valdés, Order of Malta, Chile; W. Vandersmissen, Smith Kline Beecham, Belgium; N. van der Veer, Akzonobel, Netherlands; L. Vanoyan, UMCOR, Armenia; M. Vàzquez, MSF, Spain; R.S. Villonco, Order of Malta, Philippines; J. Volkman & F.B. Bauer, Fondación San Gabriel, Bolivia; K. Weerasuriya, Department of Pharmacology, University of Colombo, Sri Lanka; D. Whyms, DFID, Bolivia; R. Wood, Samaritans Purse - World Medical Mission, USA; G. Zeana & F. Ionescu, Asociatia Salvavita, Romania.